IP Library Granted Patent US 11,339,135
Granted Patent B2
US 11,339,135 · App. 16/464,562 · Granted May 24, 2022

Method for producing triazine compound

Inventors: Takafumi Yamagami (Osaka, JP); Souta Yamasaki (Osaka, JP); Tomofumi Setsuta (Osaka, JP); Ryo Sakakibara (Osaka, JP); Yosuke Matsumura (Osaka, JP)
Assignee: MITSUBISHI TANABE PHARMA CORPORATION
C07D253/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,339,135
App. No.
16/464,562
Granted
May 24, 2022
Kind
B2
Abstract

The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof. Specifically, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of derivatizing a compound represented by formula II or a salt thereof into a corresponding compound represented by formula III, a salt thereof, or a derivative thereof, then a step of reacting the resulting compound, a salt thereof, or a derivative thereof with aminourea or a salt thereof in water to produce a compound represented by formula IV or a salt thereof, and then a step of reacting the resulting compound or a salt thereof in the presence of a base. (wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group)

Claims (100)

1. A method for producing a compound represented by formula I:

or a salt thereof, said method comprising a step of reacting a compound represented by formula IV:

or a salt thereof with a base in water, and optionally comprising a step of forming a salt thereof;

wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group.

2. The method according to claim 1 , said method comprising a step of reacting a compound represented by formula III:

a salt thereof, or a derivative thereof with aminourea or a salt thereof in water to produce the compound represented by formula IV or a salt thereof, and then a step of subjecting the resulting compound or a salt thereof to the step(s) according to claim 1 ;

wherein the derivative of formula (III) is a compound represented by formula (III′):

 and

wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group.

3. The method according to claim 2 , said method comprising a step of subjecting the compound represented by formula IV or a salt thereof without isolation to the step(s) according to claim 1 .

4. The method according to claim 3 , said method comprising a step of collecting the compound represented by formula IV or a salt thereof by filtration.

5. The method according to claim 2 , said method comprising a step of reacting a compound represented by formula II:

or a salt thereof with a glyoxalization reagent to produce the compound represented by formula III, a salt thereof, or the derivative thereof, and then a step of subjecting the resulting compound, a salt thereof, or the derivative thereof to the step(s) according to claim 2 ;

wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group.

6. The method according to claim 5 , said method comprising a step of subjecting the compound represented by formula III, a salt thereof, or the derivative thereof without isolation to the step(s) according to claim 2 .

7. The method according to claim 1 , wherein ring A is an optionally substituted monocyclic or bicyclic aryl group.

8. The method according to claim 7 , wherein ring A is a monocyclic or bicyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group.

9. A method for producing a compound represented by formula V:

or a pharmaceutically acceptable salt thereof, said method comprising

a step of producing a compound represented by formula I:

or a salt thereof by reacting a compound represented by formula IV:

or a salt thereof with a base in water, and optionally comprising a step of forming a salt thereof, and then

a step of producing the compound represented by formula V or a pharmaceutically acceptable salt thereof by a known method;

wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group and R B represents an optionally substituted aliphatic heterocyclic group.

10. The method according to claim 9 , wherein

ring A is an optionally substituted monocyclic or bicyclic aryl group; and

R B is a group represented by formula VI:

wherein X a represents CR 3a or N;

(i) when X a represents CR 3a , then

X b represents CHR 3b and X c represents O or NR 4c ,

X b represents O and X c represents NR 4c , or

X b represents NR 4b and X c represents O, NR 4c , or CHR 3c ;

(ii) when X a represents N, then

X b represents CHR 3b or C(═O) and X c represents NR 4c , or

X b represents NR 4b and X c represents CHR 3c ;

R 3a represents a hydrogen atom, a hydroxy group, an alkyl group, or an amino group;

R 3b and R 3c represent each a group independently selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkyl group;

R 4b and R 4c represent each a group independently selected from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group;

R 1 represents a hydrogen atom or an alkyl group;

R 2 represents

(i) an optionally substituted alkyl group,

(ii) an optionally substituted cycloalkyl group,

(iii) an optionally substituted aliphatic heterocyclic group,

(iv) an optionally partially hydrogenated and optionally substituted heteroaryl group, or

(v) a hydrogen atom, or

when X c represents NR 4c , then R 2 and R 4c are combined with each other at their terminals together with the nitrogen atom to which they are attached to form an aliphatic heterocyclic group optionally substituted with an optionally substituted alkyl group; and

the wavy line represents the point of attachment to the rest of molecule.

11. The method according to claim 10 , wherein

ring A is a monocyclic or bicyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group;

R B is a group represented by formula VI;

X a represents N;

X b represents CHR 3b or C(═O);

X c represents NR 4c ;

R 3b represents a group independently selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkyl group;

R 4c represents a group independently selected from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group;

R 1 represents a hydrogen atom or an alkyl group;

R 2 represents

(i) an optionally substituted alkyl group,

(ii) an optionally substituted cycloalkyl group,

(iii) an optionally substituted aliphatic heterocyclic group,

(iv) an optionally partially hydrogenated and optionally substituted heteroaryl group, or

(v) a hydrogen atom, or

R 2 and R 4c are combined with each other at their terminals together with the nitrogen atom to which they are attached to form an aliphatic heterocyclic group optionally substituted with an optionally substituted alkyl group.

12. The method according to claim 11 , wherein

ring A is a monocyclic or bicyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group;

R B is a group represented by formula VI;

X a represents N;

X b represents CHR 3b ;

X c represents NR 4c ;

R 3b represents a group independently selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkyl group;

R 4c represents a group independently selected from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group;

R 1 represents a hydrogen atom or an alkyl group;

R 2 represents

(i) an optionally substituted alkyl group,

(ii) an optionally substituted cycloalkyl group, or

(iii) an optionally substituted aliphatic heterocyclic group.

13. The method according to claim 12 , wherein

ring A is a monocyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group;

R B is a group represented by formula VI;

X a represents N;

X b represents CH 2 ;

X c represents NH;

R 1 represents a hydrogen atom;

R 2 represents an optionally substituted cycloalkyl group.

14. The method according to claim 13 , wherein

ring A is a phenyl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group;

R B is a group represented by formula VI;

X a represents N;

X b represents CH 2 ;

X c represents NH;

R 1 represents a hydrogen atom;

R 2 represents an optionally substituted cyclohexyl group.

15. The method according to claim 14 , wherein

ring A is 4-methylphenyl;

R B is a group represented by formula VI;

X a represents N;

X b represents CH 2 ;

X c represents NH;

R 1 represents a hydrogen atom;

R 2 represents an optionally substituted cyclohexyl group.

Assignments (2)
CHANGE OF NAME Recorded Mar 5, 2026
From: MITSUBISHI TANABE PHARMA CORPORATION
To: TANABE PHARMA CORPORATION
Reel/Frame 073977/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2019
From: YAMAGAMI, TAKAFUMI; YAMASAKI, SOUTA; SETSUTA, TOMOFUMI; SAKAKIBARA, RYO; MATSUMURA, YOSUKE
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 049309/0595 →
Priority Claims (1)
JP JP2016-232890 · Nov 30, 2016 · national
Continuity (1)
Related Publication 20210380541A1 · Dec 9, 2021